摘要
目的 研究宫颈癌(CC)组织F盒蛋白22(FBXO22),ETS转录因子4(ELK4)的表达及与病理参数及根治术术后肿瘤进展的关系。方法 收集2020年1月至2021年2月期间商洛市中心医院治疗的105例CC患者。采用qPCR和免疫组化检测CC组织FBXO22,ELK4的mRNA和蛋白表达。Pearson相关分析CC组织中FBXO22 mRNA与ELK4 mRNA的相关性。Log-Rank检验比较不同FBXO22、ELK4表达CC患者K-M生存曲线的差异。采用COX回归模型分析CC预后影响因素。结果 CC癌组织中FBXO22、ELK4 mRNA和蛋白阳性率表达均高于癌旁组织(均P<0.001)。CC中FBXO22 mRNA与ELK4 mRNA表达呈正相关(r=0.803,P<0.001)。FIGO分期ⅠB2~ⅡB期患者CC癌组织FBXO22 mRNA和蛋白,ELK4 mRNA和蛋白高于ⅠA~ⅠB1期患者,差异具有统计学意义(均P<0.05)。FBXO22 mRNA高表达组和低表达组3年无进展生存率分别为60.00%(30/50),81.82%(45/55),ELK4 mRNA高表达组和低表达组3年无进展生存率分别为59.62%(31/52),83.02%(44/53)(均P<0.05)。FBXO22阳性组和阴性组3年无进展生存率分别为67.07%(55/82),86.96%(20/23)(P<0.05)。ELK4阳性组和阴性组3年无进展生存率分别为66.25%(53/80),88.00%(22/25)(P<0.05)。FIGO分期ⅠB2~ⅡB期,FBXO22 mRNA高或蛋白阳性,ELK4 mRNA高或蛋白阳性是影响CC患者预后的危险因素(均P<0.001)。结论 CC中FBXO22、ELK4表达均显著升高,两者协同促进CC的肿瘤进展,是新的评估CC预后的标志物。
Objective To investigate the expression of F-box protein 22(FBXO22)and ETS transcription factor 4(ELK4)in cervical cancer(CC),and to analyze their relationship with pathological parameters and tumor progression after radical surgery.Method 105 cases of CC patients treated in Shangluo Central Hospital from January 2020 to February 2021 were collected.The mRNA and protein expression of FBXO22 and ELK4 in CC tissue were analyzed by qPCR and immunohistochemistry.The correlation between FBXO22 mRNA and ELK4 mRNA were analyzed by Pearson correlation analysis.The differences in K-M survival curves among CC patients with different FBXO22 and ELK4 expression groups were compared by Log-Rank test.COX regression model was used to analyze the prognostic factors of CC.Results The positive rates of FBXO22,ELK4 mRNA and protein expression in CC tissues were higher than those in adjacent tissues(all P<0.001).FBXO22 mRNA and ELK4 mRNA expression in CC was positively correlated(r=0.803,P<0.001).FBXO22 mRNA and protein,ELK4 mRNA and protein in patients with FIGO stage Ⅰ B2-Ⅱ B were significantly higher than those in patients with stage Ⅰ a-Ⅰ B1(all P<0.05).The 3-year progression free survival rates were 60.00%(30/50)and 81.82%(45/55)in the high and low expression groups of FBX022 mRNA,and 59.62%(31/52)and 83.02%(44/53)in the high and low expression groups of ELK4 mRNA,respectively(all P<0.05).The 3-year progression free survival rates of the FBXO22 positive group and the FBXO22 negative group were 67.07%(55/82)and 86.96%(20/23),respectively(P<0.05).The 3-year progression free survival rate of ELK4 positive group and ELK4 negative group were 66.25%(53/80)and 88.00%(22/25)(P<0.05).In FIGO stage Ⅰ B2-ⅡB,high mRNA or protein expression of FBXO22 and high mRNA or protein expression of ELK4 were risk factors affecting the prognosis of CC patients(all P<0.001).Conclusion The expression of FBXO22 and ELK4 in CC are significantly increased,both of them plays synergistically role in promoting tumor progression in CC.They are new biomarkers for evaluating the prognosis of CC.
作者
潘蕊莲
吴媛媛
何文艳
PAN Ruilian;WU Yuanyuan;HE Wenyan(Department of Gynaecology,Shangluo Central Hospital,Shangluo,Shaanxi 726000,China;Department of Pathology,Shangluo Central Hospital,Shangluo,Shaanxi 726000,China)
出处
《中国优生与遗传杂志》
2025年第3期609-614,共6页
Chinese Journal of Birth Health & Heredity
基金
陕西省卫生健康委科研项目(2020D0036)。
关键词
宫颈癌
F盒蛋白22
ETS转录因子4
预后
cervical cancer
F-box protein 22
ETS transcription factor 4
prognosis
